S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bruker Co. stock logo
BRKR
Bruker
$82.94
-1.1%
$87.48
$53.79
$94.86
$11.42B1.17771,511 shs688,770 shs
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$5.92
-0.8%
$7.32
$3.80
$12.31
$774.45M1.37749,317 shs709,469 shs
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
$22.29
-1.6%
$23.46
$14.10
$26.01
$2.77B0.5692,710 shs646,366 shs
10x Genomics, Inc. stock logo
TXG
10x Genomics
$29.16
-5.3%
$40.59
$29.12
$63.57
$3.47B1.91.44 million shs2.91 million shs
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bruker Co. stock logo
BRKR
Bruker
-2.17%-6.81%-8.91%+20.36%+1.57%
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-0.83%-13.60%-14.10%-24.91%-41.59%
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
-0.35%-2.12%-5.31%-9.47%-0.57%
10x Genomics, Inc. stock logo
TXG
10x Genomics
-6.27%-17.58%-15.22%-26.49%-42.64%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bruker Co. stock logo
BRKR
Bruker
4.773 of 5 stars
2.24.01.73.82.14.23.1
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
1.9846 of 5 stars
3.30.00.00.03.73.30.6
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
1.12 of 5 stars
2.05.00.00.03.10.00.6
10x Genomics, Inc. stock logo
TXG
10x Genomics
4.1506 of 5 stars
3.42.00.04.82.33.30.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bruker Co. stock logo
BRKR
Bruker
2.43
Hold$84.862.31% Upside
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
2.60
Moderate Buy$9.0052.03% Upside
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
2.00
Hold$26.0016.64% Upside
10x Genomics, Inc. stock logo
TXG
10x Genomics
2.88
Moderate Buy$60.88108.76% Upside

Current Analyst Ratings

Latest TXG, BRKR, OLK, and CTKB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2024
Bruker Co. stock logo
BRKR
Bruker
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSell ➝ Sell$66.00 ➝ $74.00
4/10/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$55.00 ➝ $45.00
3/26/2024
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$26.00
3/26/2024
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold$26.00
3/6/2024
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$11.00 ➝ $10.00
3/1/2024
Bruker Co. stock logo
BRKR
Bruker
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$94.00 ➝ $102.00
2/29/2024
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$9.00 ➝ $10.00
2/16/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$68.00 ➝ $63.00
2/15/2024
Bruker Co. stock logo
BRKR
Bruker
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$86.00 ➝ $94.00
2/14/2024
Bruker Co. stock logo
BRKR
Bruker
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$80.00 ➝ $95.00
2/14/2024
Bruker Co. stock logo
BRKR
Bruker
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$63.00 ➝ $81.00
(Data available from 4/17/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bruker Co. stock logo
BRKR
Bruker
$2.96B3.85$3.46 per share24.00$10.08 per share8.23
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$193.01M4.01$0.02 per share238.67$2.90 per share2.04
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
$169.60M16.34N/AN/A$4.04 per share5.52
10x Genomics, Inc. stock logo
TXG
10x Genomics
$618.73M5.62N/AN/A$6.22 per share4.69

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bruker Co. stock logo
BRKR
Bruker
$427.20M$2.9228.4024.112.1814.41%29.94%9.68%5/2/2024 (Estimated)
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-$12.15M-$0.09N/A84.57N/A-6.29%-1.40%-1.13%5/14/2024 (Estimated)
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
-$31.60M-$0.25N/A557.25N/A-18.63%-6.50%-5.63%5/9/2024 (Estimated)
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$255.10M-$2.17N/AN/AN/A-41.17%-28.82%-22.67%4/30/2024 (Confirmed)

Latest TXG, BRKR, OLK, and CTKB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2024N/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$0.46N/A+$0.46N/AN/AN/A  
3/25/2024Q4 2023
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
$0.14-$0.06-$0.20-$0.06$82.80 million$68.55 million
2/15/2024Q4 2023
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$0.36-$0.41-$0.05-$0.41$182.73 million$183.98 million    
2/13/202412/31/2023
Bruker Co. stock logo
BRKR
Bruker
$0.65$0.70+$0.05-$0.01$809.35 million$844.50 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bruker Co. stock logo
BRKR
Bruker
$0.200.24%+7.72%6.85%N/A
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/AN/AN/AN/AN/A
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
N/AN/AN/AN/AN/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
N/AN/AN/AN/AN/A

Latest TXG, BRKR, OLK, and CTKB Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/15/2024
Bruker Co. stock logo
BRKR
Bruker
Quarterly$0.050.25%2/29/20243/1/20243/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bruker Co. stock logo
BRKR
Bruker
0.83
1.80
0.99
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/A
6.97
5.89
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
N/A
4.75
3.55
10x Genomics, Inc. stock logo
TXG
10x Genomics
N/A
4.69
4.11

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Bruker Co. stock logo
BRKR
Bruker
79.52%
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
69.46%
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
30.19%
10x Genomics, Inc. stock logo
TXG
10x Genomics
84.68%

Insider Ownership

CompanyInsider Ownership
Bruker Co. stock logo
BRKR
Bruker
28.20%
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
15.90%
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
N/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
10.65%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Bruker Co. stock logo
BRKR
Bruker
9,707137.67 million98.85 millionOptionable
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
676130.82 million110.02 millionOptionable
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
707124.34 millionN/AOptionable
10x Genomics, Inc. stock logo
TXG
10x Genomics
1,259119.17 million106.48 millionOptionable

TXG, BRKR, OLK, and CTKB Headlines

SourceHeadline
10x Genomics, Inc. (TXG)10x Genomics, Inc. (TXG)
finance.yahoo.com - April 17 at 12:34 PM
10x Genomics (NASDAQ:TXG) Trading Down 5.9%10x Genomics (NASDAQ:TXG) Trading Down 5.9%
marketbeat.com - April 16 at 1:41 PM
10x Genomics, Inc. (NASDAQ:TXG) Shares Bought by Sumitomo Mitsui Trust Holdings Inc.10x Genomics, Inc. (NASDAQ:TXG) Shares Bought by Sumitomo Mitsui Trust Holdings Inc.
marketbeat.com - April 16 at 7:22 AM
SVB Wealth LLC Has $80.95 Million Position in 10x Genomics, Inc. (NASDAQ:TXG)SVB Wealth LLC Has $80.95 Million Position in 10x Genomics, Inc. (NASDAQ:TXG)
marketbeat.com - April 15 at 10:06 PM
10x Genomics (NASDAQ:TXG) Hits New 52-Week Low at $33.4710x Genomics (NASDAQ:TXG) Hits New 52-Week Low at $33.47
marketbeat.com - April 15 at 2:48 PM
10x Genomics (NASDAQ:TXG) Shares Gap Down  After Analyst Downgrade10x Genomics (NASDAQ:TXG) Shares Gap Down After Analyst Downgrade
americanbankingnews.com - April 12 at 5:26 AM
Cathie Woods ARK focuses on Teladoc and 10X Genomics stockCathie Wood's ARK focuses on Teladoc and 10X Genomics stock
investing.com - April 11 at 7:21 PM
10x Genomics (NASDAQ:TXG) Price Target Cut to $45.00 by Analysts at Barclays10x Genomics (NASDAQ:TXG) Price Target Cut to $45.00 by Analysts at Barclays
americanbankingnews.com - April 11 at 4:58 AM
10x Genomics to Report First Quarter 2024 Financial Results on April 30, 202410x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024
finance.yahoo.com - April 10 at 7:03 PM
10x Genomics (NASDAQ:TXG) Price Target Cut to $45.0010x Genomics (NASDAQ:TXG) Price Target Cut to $45.00
marketbeat.com - April 10 at 4:19 PM
10x Genomics to Report First Quarter 2024 Financial Results on April 30, 202410x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024
prnewswire.com - April 10 at 4:05 PM
10x Genomics (NASDAQ:TXG) Shares Gap Down to $37.3710x Genomics (NASDAQ:TXG) Shares Gap Down to $37.37
marketbeat.com - April 10 at 11:50 AM
Baillie Gifford & Co. Decreases Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG)Baillie Gifford & Co. Decreases Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG)
marketbeat.com - April 9 at 12:12 PM
As 10x Launches Visium HD, Will Single Cell Resolution Draw New Customers?As 10x Launches Visium HD, Will Single Cell Resolution Draw New Customers?
genengnews.com - March 29 at 5:58 PM
ARK Investment Management LLC Acquires 1,047,827 Shares of 10x Genomics, Inc. (NASDAQ:TXG)ARK Investment Management LLC Acquires 1,047,827 Shares of 10x Genomics, Inc. (NASDAQ:TXG)
marketbeat.com - March 28 at 6:39 AM
10x Genomics, Inc. (NASDAQ:TXG) Shares Acquired by Vanguard Group Inc.10x Genomics, Inc. (NASDAQ:TXG) Shares Acquired by Vanguard Group Inc.
marketbeat.com - March 27 at 4:25 AM
10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay
finance.yahoo.com - March 26 at 1:11 PM
10x Genomics, Inc: 10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel10x Genomics, Inc: 10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel
finanznachrichten.de - March 23 at 12:22 PM
10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel
finance.yahoo.com - March 21 at 4:46 PM
TXG Nov 2024 40.000 putTXG Nov 2024 40.000 put
ca.finance.yahoo.com - March 16 at 2:48 PM
TXG Aug 2024 60.000 callTXG Aug 2024 60.000 call
ca.finance.yahoo.com - March 16 at 1:47 PM
TXG Dec 2024 40.000 putTXG Dec 2024 40.000 put
ca.finance.yahoo.com - March 16 at 1:47 PM
Insider Selling: 10x Genomics, Inc. (NASDAQ:TXG) CEO Sells 4,660 Shares of StockInsider Selling: 10x Genomics, Inc. (NASDAQ:TXG) CEO Sells 4,660 Shares of Stock
insidertrades.com - March 16 at 9:43 AM
TXG Apr 2024 60.000 callTXG Apr 2024 60.000 call
finance.yahoo.com - March 16 at 12:31 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Bruker logo

Bruker

NASDAQ:BRKR
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Cytek Biosciences logo

Cytek Biosciences

NASDAQ:CTKB
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Olink Holding AB (publ) logo

Olink Holding AB (publ)

NASDAQ:OLK
Olink Holding AB (publ) develops, produces, markets, and sells biotechnological products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focuses on life science research. The company's products include Olink Explore that consist of Explore 372 and Explore 384 for cardiovascular and metabolic, oncology, neurology, and inflammation diseases; Olink Target product line; Olink Flex, a low-plex applications and use-cases; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on. Its products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and data analysis and bioinformatics services. In addition, the company offers Olink normalized protein expression (NPX) data processing software, a purpose-built software that enable users to import data, perform data analysis including visualizations, and statistical modelling; and Olink Insight, a cloud platform for Olink community to accelerate proteomics. It sells its products and services through its own direct sales force in Sweden, the United States, rest of the Americas, rest of Europe, the Middle East, Africa, Japan, and internationally. The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021. Olink Holding AB (publ) was founded in 2004 and is headquartered in Uppsala, Sweden.
10x Genomics logo

10x Genomics

NASDAQ:TXG
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.